Aug 3, 2026 · 13 min · 6 segments
The treatment landscape for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO) continues to evolve, with…
Richard GaleHost
Michael StewartGuest
Carl DanzigGuestYou are now listening to MedEdTalks, a Vindico Medical Education production.
This podcast is eligible for CE credit.
For details, please view the episode notes or CE information.
Now, here's your host.
Hello and welcome to updates from the American Society of Retinal Specialists, Neovascular AMD, Diabetic Macleodema, Diabetic Retinopathy and Retinal Vein Occlusion Treatment.
This is a continuing education activity and is provided by Vindico Medical Education and is supported by an independent medical education grant from Regeneron Pharmaceuticals.
My name is Richard Gale, Professor of Ophthalmology from the Hull York Medical School, University of York, and Honorary Consultant Medical Ophthalmologist at the York and Scarborough Teaching Hospitals NHS Foundation Trust in York, United Kingdom.
And it's my pleasure to be joined today by my expert colleagues, Carl Danzig, Rental Specialist in Advanced Rent Institute in Bonneta Springs, Florida, and Affiliate Assistant Professor of Clinical Biomedical Science at the Charles E. Schmidt College of Medicine, Florida, Atlantic University in Boca Raton.
and Michael Stewart, Professor and Chairman Emeritus of Ophthalmology at the Knight Templar Eye Foundation and Professor of Ophthalmology Research at the Mayo Clinic, Florida in Jacksonville.
In this activity, we'll be discussing how recent clinical data on approved second-generation anti-VEGF therapies inform management for patients with renal diseases and how they could and indeed should be integrated into their current treatment paradigms.
Read the full transcript.
Create an account to read the whole episode, search across every transcript, and follow the shows you care about.
You are now listening to MedEdTalks, a Vindico Medical Education production.
This podcast is eligible for CE credit.
For details, please view the episode notes or CE information.
Now, here's your host.
Hello and welcome to updates from the American Society of Retinal Specialists, Neovascular AMD, Diabetic Macleodema, Diabetic Retinopathy and Retinal Vein Occlusion Treatment.
This is a continuing education activity and is provided by Vindico Medical Education and is supported by an independent medical education grant from Regeneron Pharmaceuticals.
My name is Richard Gale, Professor of Ophthalmology from the Hull York Medical School, University of York, and Honorary Consultant Medical Ophthalmologist at the York and Scarborough Teaching Hospitals NHS Foundation Trust in York, United Kingdom.
And it's my pleasure to be joined today by my expert colleagues, Carl Danzig, Rental Specialist in Advanced Rent Institute in Bonneta Springs, Florida, and Affiliate Assistant Professor of Clinical Biomedical Science at the Charles E. Schmidt College of Medicine, Florida, Atlantic University in Boca Raton.
and Michael Stewart, Professor and Chairman Emeritus of Ophthalmology at the Knight Templar Eye Foundation and Professor of Ophthalmology Research at the Mayo Clinic, Florida in Jacksonville.
In this activity, we'll be discussing how recent clinical data on approved second-generation anti-VEGF therapies inform management for patients with renal diseases and how they could and indeed should be integrated into their current treatment paradigms.
